Stromedix

Stromedix is a biopharmaceutical company dedicated to developing therapies for organ failure due to fibrosis. Initially, it will concentrate on chronic indications, utilizing its expertise to remodel tissues affected by this condition. In the future, Stromedix plans to expand its therapeutic pipeline to address related areas, including acute organ failure and cancer. Through its innovative approach, the company aims to provide effective treatments that improve patient outcomes in these challenging medical contexts.